Fig. 2From: Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional respondersKaplan-Meier curves for progression-free survival (PFS) of patients with metastatic MITF family translocation renal cell carcinoma treated with (a) a tyrosine kinase inhibitor (TKI) or (b) an immune checkpoint inhibitor (ICI)Back to article page